McKesson (MCK)
(Delayed Data from NYSE)
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists
by Zacks Equity Research
IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.
Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.
Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.
Quidel Corporation (QDEL) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.
Here's Why You Should Retain Thermo Fisher (TMO) For Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
Here's Why You Should Hold on to Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens (WBA) owing to the recent product launches.
The Zacks Analyst Blog Highlights Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group
by Zacks Equity Research
Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group are part of top Analyst Blog.
Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space
by Zacks Equity Research
Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.
Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth
by Zacks Equity Research
In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.
STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.
Here's Why You Should Retain Charles River (CRL) Stock For Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.
Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.
Zacks.com featured highlights include The Kroger, NVIDIA, Jones Lang LaSalle, Paychex and McKesson
by Zacks Equity Research
The Kroger, NVIDIA, Jones Lang LaSalle, Paychex and McKesson are part of today's Screen of the Week article.
Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes
by Zacks Equity Research
Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.
Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022
by Riya Anand
Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.
Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects
by Zacks Equity Research
Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.
Here's Why You Should Hold on to Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer
by Zacks Equity Research
Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.
Walgreens (WBA) Expands Medical Care Offerings in California
by Zacks Equity Research
Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.
5 Dividend Growth Stocks for Safe Income Amid Volatility
by Sweta Killa
The Kroger (KR), NVIDIA (NVDA), Jones Lang LaSalle (JLL), Paychex (PAYX) and McKesson (MCK) could be compelling picks amid market volatility.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.